You are here: Industry Insights > MSA

News List

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial prnasia
December 15, 2021
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions...
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function prnasia
July 16, 2021
Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced that Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society ...
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial prnasia
June 24, 2021
Alterity Therapeutics Limited has received guidance from the European Medicines Agency (EMA) regarding key aspects of the Company's Phase 2 clinical trial for investigational drug ATH434 in the treatment of Multiple System Atrophy (MSA).
Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report Alterity Therapeutics Limited
May 17, 2021
Most of the company's efforts were focused on the bioMUSE Natural History study in MSA patients being conducted at Vanderbilt University Medical Center. This study will provide important information.
Plus Therapeutics, Piramal Ink Master Services Agreement contractpharma
March 24, 2021
Plus Therapeutics has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and supply of Plus’ Rhenium NanoLiposome (RNL) intermediate drug product.
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases prnasia
November 17, 2020
Alterity Therapeutics has announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).
Biohaven's Verdiperstat Receives Fast Track Designation for Multiple System Atrophy Treatment americanpharmaceuticalreview
March 19, 2020
Biohaven Pharmaceutical announced the Company's myeloperoxidase (MPO) inhibitor, verdiperstat, received Fast Track designation from the US Food and Drug Administration (FDA) ...
Verdiperstat Receives Orphan Drug Designation from FDA for Multiple System Atrophy americanpharmaceuticalreview
February 20, 2019
Biohaven announced it received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its product candidate verdiperstat (previously BHV-3241)....